Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China
(Adnkronos) – SHANGHAI, March 31, 2023 /PRNewswire/ — Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy (TRT) to benefit cancer patients in China, today announced the development plans
